Pune based firm set to manufacture a billion doses
Serum Institute is the largest maker of vaccines in the world. Serum Institute of India is investing USD 100 million on a potential Covid-19 Oxford vaccine. The Pune-based company has partnered with AstraZeneca. AstrZeneca a British biopharma company. It is ready to supply the AZD1222 vaccine doses to India and other countries under the same economic bracket.
The CEO of SII gives a statement on Oxford Vaccine
Adar Poonawalla, the CEO of SII, says that the manufacturing facility is ready and they plan to start production in two months. He further says that they are spending more than USD 100 million for this facility. The company will not distribute the vaccines either in India or anywhere else in the world until the trials complete successfully for safety and effectiveness.
People are keen to know when and how many vaccines will be available in India. To this Mr. Poonawalla answers that it is a bit early to comment on a specific number. He also says that the SII had requested the Central government to give permission to make the first usage of the vaccine for its employees who were at high risk of contracting the virus.
Suresh Jadhav, Executive Director of the Pune-based Serum Institute of India said the company will start manufacturing small quantities of the vaccine if the Phase-1 trial results are encouraging. “We will begin manufacturing two-three million doses of the vaccine if the Phase-1 trial results, which are expected in the first week of July, are successful,” said Mr. Jadhav while talking to few media channels. “Millions of more doses will be manufactured once the Phase 2-3 trial is completed”, he added.
The Oxford vaccine has shown effective results in the second phase of the trial. SII has started its work on manufacturing the vaccine. It may be the beginning of a hopeful future for people all around the world.